Kesar Prajapati

Kesar Prajapati

Auto-generated profile, based on publicly available information

Kesar Prajapati

Division of Medicine, Metropolitan Hospital Center, NYC Health+, New York City, NY 10029, United States

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 May 2021 in BMJ Case Reports
Verified
Journal Article
Closed access
PDF file
KPKesar Prajapati
Kesar Prajapati
VSVikranti Sailor
Vikranti Sailor
SPSavan Patel
Savan Patel
MRMalay Rathod
Malay Rathod
This case of recurrent cerebral venous thrombosis (CVT) highlights hyperhomocysteinemia in pernicious anemia due to vitamin B12 deficiency. No other risk factors such as trauma, infections, coagulation disorders or autoimmune diseases were present. The patient was cured with vitamin B12 and anticoagulation therapy. So, it is worthwhile and important to investigate levels of vitamin B12 and homocysteine in CVT.

24 March 2021 in BMJ Case Reports
Verified
Journal Article
Closed access
PDF file
KPKesar Prajapati
Kesar Prajapati
JPJaya Pathak
Jaya Pathak
VSVikranti Sailor
Vikranti Sailor
Parth AdrejiyaParth Adrejiya
Parth Adrejiya
Ellis-van Creveld (EVC) syndrome is a relatively rare chondroectodermal dysplasia considered mainly as a generalised disorder of the maturation of endochondral ossification. Congenital heart disease occurs in approximately half of the patients with EVC syndrome, 60% of which is a common atrium. Common atrium is a rare variety of interatrial communication characterised by absence or virtual absence of the atrial septum. Patients with this syndrome rarely survive to an old age. We report a case of EVC who presented for the first time at 60 years of age, as survival to an advanced age is exceptional in case of EVC.

28 April 2025 in Catheterization and Cardiovascular Interventions
Verified
Journal Article
Closed access
KPKesar Prajapati
Kesar Prajapati
SLShanmukh sai pavan Lingamsetty
Shanmukh sai pavan Lingamsetty
HTHarshith Thyagaturu
Harshith Thyagaturu
PEPhillip Englund
Phillip Englund
VSVijaykumar Sekar
Vijaykumar Sekar
VJVikrant Jagadeesan
Vikrant Jagadeesan

18 June 2026 in Clinical and Translational Oncology
Verified
Journal Article
Open access
TTThanmai Reddy Thugu
Thanmai Reddy Thugu
KPKesar Prajapati
Kesar Prajapati
AAAhmad Alhomaid
Ahmad Alhomaid
MJMuskan Jain
Muskan Jain
NSNeha Singh
Neha Singh
AJAkhil Jain
Akhil Jain
Background: Cetuximab is an EGFR inhibitor used in metastatic colorectal cancer (mCRC). It demonstrates significant response variability even among RAS wild-type patients, with only ~65% objective response rates as first-line therapy. Current biomarkers, including RAS and BRAF mutation status, are insufficient to fully predict cetuximab efficacy. MicroRNA-31 (miR-31-3p and miR-31-5p) has emerged as a potential predictive biomarker through its role in activating the RAS signaling pathway by suppressing RAS p21 GTPase activating protein 1 (RASA1). This systematic review evaluates the evidence on miR-31 as a predictive biomarker for cetuximab response in mCRC. Methods: A systematic literature search was conducted using PubMed/MEDLINE and Google Scholar through May 2026. Original studies evaluating miR-31 expression in relation to cetuximab response in mCRC were included. Data extraction was performed by two independent reviewers. Quality was assessed using the Newcastle-Ottawa Scale for observational studies and the Cochrane Risk-of-Bias tool for clinical trials. The study followed PRISMA 2020 guidelines. Results: Eleven studies (3 clinical trials, 8 observational/retrospective studies; sample sizes 26–370) were included, with moderate to high quality scores. Low miR-31-3p expression was consistently associated with improved cetuximab outcomes. In the FIRE-3 trial, low miR-31-3p expressers demonstrated superior overall survival (HR: 0.61; P = 0.01), progression-free survival (HR: 0.74; P = 0.05), and overall response rate (OR: 4.0; P = 0.01) with cetuximab versus bevacizumab. The PROSPECT-C trial showed better response rates (58.3% vs. 22.2%; P = 0.029) and longer progression-free survival with low expression. Conversely, elevated miR-31 expression was associated with shorter progression-free survival. Notably, miR-31-3p did not predict anti-EGFR efficacy in right-sided tumors. Conclusion: MiR-31-3p is a promising predictive biomarker for cetuximab response in RAS wild-type mCRC, with low expression consistently associated with improved outcomes. However, tumor sidedness may modulate its predictive value. Prospective validation studies with standardized assays are needed before clinical implementation. Integration of miR-31-3p with existing markers could help identify patients unlikely to benefit from anti-EGFR therapy.

1 November 2025 in Current Cardiology Reviews
Verified
Journal Article
Open access
PDF file
ASAakash R. Sheth
Aakash R. Sheth
HPHarsh P. Patel
Harsh P. Patel
KPKrutharth Pandya
Krutharth Pandya
STSamarthkumar Thakkar
Samarthkumar Thakkar
KPKesar Prajapati
Kesar Prajapati
ADAbhishek Deshmukh
Abhishek Deshmukh
Introduction: Advances in cardiac implanted electronic devices (CIED) have significantly improved outcomes for patients with heart failure. However, there is a bereft of recent real- world data on the relative effectiveness of cardiac resynchronization therapy with pacing and defibrillator (CRT-D) and continuous resynchronization therapy with pacing (CRT-P) in patients with nonischemic cardiomyopathy (NICM). We hypothesized that the addition of defibrillation therapy in patients with NICM would offer no significant benefit. Methods: We searched the National Readmissions Database (NRD) from 2016-2020 to identify hospitalizations with NICM using appropriate ICD-10 diagnosis and procedure codes. The cohort was further divided into groups with NICM and CRT-D implantation and NICM with CRTP implantation. Results and Discussion: Our final cohort included 8,801 hospitalizations with NICM and CRT-D implantation and 3,399 hospitalizations with NICM and CRT-P implantation. Propensity matching was performed using comorbidities through multivariate logistic regression. Two thousand nine hundred seventeen hospitalizations were included in each of the two groups, CRT-D and CRT-P. Analysis of the propensity-matched cohorts at 180 days revealed a trend toward lower heart failure readmission, all-cause readmission, and all-cause mortality rates in the group with CRTP implantation. However, there was no difference noted in the 180-day hazard ratios of HF readmission [1.08 (0.98-1.19); p = 0.1], all-cause readmission [1.04 (0.87-1.12); p = 0.23], and all-cause mortality [0.83 (0.58-1.19); p = 0.32]. Conclusion: It was found that NICM patients with CRT-D have a trend towards higher HF readmissions, all-cause readmission, and all-cause mortality compared to those with CRT-P, but no significant difference was noted in hazard ratios. The findings of our study raise further questions about the need for defibrillator therapy in patients with NICM and merit further studies to better select candidates for each of these therapies.